EXG102-031

BIOLOGICAL2 trials

Sponsors

Exegenesis Bio, Hangzhou Jiayin Biotech Ltd

Conditions

Neovascular (Wet) Age-related Macular Degeneration (nAMD)Neovascular Age-related Macular Degeneration

Phase 1

A Study of EXG102-031 in Patients With wAMD (Everest)

CompletedNCT05903794

Exegenesis BioNeovascular (Wet) Age-related Macular Degeneration (nAMD)

Start: 2023-07-24End: 2026-02-16Updated: 2026-04-08

A Study of EXG102-031 in Participants With wAMD

RecruitingNCT06183814

Hangzhou Jiayin Biotech LtdNeovascular Age-related Macular Degeneration

Start: 2023-10-12End: 2025-12-31Target: 42Updated: 2024-01-09